In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report), with a ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research ...

JMP Securities reiterated its Market Outperform rating on Protagonist Therapeutics (NASDAQ:PTGX) with a steady price target ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from $51.00 to $53.00 in a research note issued to investors on ...

John Hussman Reduces Stake in Barrick Gold Corp by 68%, Impacting Portfolio by -2.11% ...

Truist Securities reiterated its Buy rating and $60.00 price target for Protagonist Therapeutics (NASDAQ:PTGX) shares, which currently trade at $38.78 with a market capitalization of $2.3 billion. The ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) announced that it has initiated a phase II study to evaluate its novel hepcidin mimetic candidate, PTG-300, in patients with... Puma Biotechnology ...

Protagonist Pictures is launching world sales at the EFM on Australian filmmaker Nicholas Clifford time travelling romantic ...

Protagonist Pictures will launch Stan Original rom-com 'One More Shot' for international sales at this year's European Film ...